Navigation Links
Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
Date:8/22/2011

orming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
2. Echo Therapeutics Announces Second Quarter 2011 Financial Results
3. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
4. Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription
5. Echo Therapeutics Unveils Symphony tCGM Demonstration Video
6. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
7. Echo Therapeutics Announces Multiple Patents and Trademark Grants
8. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
9. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
10. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
11. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & General ... Conference on Thursday, May 30, 2013, in New ... The Company,s presentation is scheduled to begin at ... webcast. To access the webcast, go to www.atossagenetics.com . ...
(Date:5/16/2013)... and ZURICH , May 17, ... Agency for Science, Technology and Research (A*STAR) and ... first healthy volunteer has been dosed in a Phase 1 ... Cytos, proprietary bacteriophage Qbeta virus-like particle (VLP) technology. In this ... this novel vaccine candidate and its potential to protect against ...
(Date:5/16/2013)... , May 16, 2013  HeartWare International, Inc. (NASDAQ: ... of less invasive, miniaturized circulatory support technologies that are revolutionizing ... Doug Godshall is scheduled to present ... EDT on Monday, May 20, 2013.  The conference is being ... A live webcast of the Company,s presentation at ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... of data from more than 12,000 people with cystic fibrosis ... infection in the Cystic Fibrosis Foundation,s Patient Registry shows that ... associated with a 21% reduction in mortality in the following ... North American Cystic Fibrosis Conference (NACFC) in Baltimore, Maryland, sponsored ...
... Bionovo, Inc. (Nasdaq: BNVI ) today announced ... discussing new classes of estrogen receptor modulating drugs with ... in the most recent edition of Current Opinion ... Specific Target Genes and Biological Responses by Estrogen Receptor ...
Cached Medicine Technology:Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 2Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 3Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 4Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 5Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 2Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 3Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 4
(Date:5/18/2013)... The “World Healthcare IT Market: Trends ... major market drivers, restraints, and opportunities in North America, ... , 89 market data tables ... "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... , The global healthcare IT market is expected to ...
(Date:5/18/2013)... York, New York (PRWEB) May 18, 2013 ... to mount in courts throughout the country, Bernstein Liebhard ... metal-on-metal hip replacement patients often suffer tissue damage before ... the study, which according to Science Daily will appear ... metal-on-metal hip replacement recipients underwent MRI screens of their ...
(Date:5/18/2013)... 2013 The “Sleep Apnea Diagnostic & ... Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] ... analyzes and studies the major market drivers, restraints, and ... the World. , Browse , ... Figures , 318 pagesand in-depth TOC ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The Ayurvedic ... ayurvedic education institution in the West. Program is available ... , Ayurveda is a healing modality practiced for over ... it is considered that health begins when an individual ... understanding of their individual needs. Ayurveda aims to heal ...
(Date:5/18/2013)... Los Angeles, Ca (PRWEB) May 18, 2013 ... lot of people. But among the horde of new weight ... the one most talked about. Recent studies about this newest ... to achieve one’s ideal body shape. , Garcinia Cambogia is ... looks like a tamarind. Eating the fruit can suppress a ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... by Dr Christina Haston, a researcher of the McGill ... on the bone problems that generally accompany cystic fibrosis. ... to this bone frailty, a finding which may have ... published on February 1, 2008 in the American Journal ...
... Community Leaders and Members on National Black,HIV/AIDS Awareness ... Cafeteria to Address Health Disparities, BOSTON, Feb. ... Massachusetts Black Legislative Caucus (MBLC) are calling on,members ... to respond to "An Added,Burden: The Impact of ...
... NEW YORK, Feb. 7 Brand teams at a ... skills to the next,level at a day-long Tech Fit ... Healthcare Communications Group (SSHCG) headquarters in lower,Manhattan., According ... usual show,and tell one-off. It is the latest innovation ...
... Workers Urge Senators Baucus and Grassley to,Stop Bush Medicare ... to the Bush,Administration,s budget plan cutting U.S. seniors, Medicare-financed,nursing ... Coalition to Protect,Senior Care (CPSC) today called the proposal ... a news briefing that they will launch a,new effort ...
... fat and protein, risk did not increase, study claims , , ... carbohydrates but high in animal fat and protein doesn,t seem ... a new study claims. , "One study is never enough ... that it shows that a low-fat diet is no better ...
... The National Business Group on,Health (NBGH) and the ... on Monday, Feb. 11, 2008 at 1:30 p.m. EST ... and ethnic health disparities,and improve the quality of health ... to bring business, medicine, and public health,together to develop ...
Cached Medicine News:Health News:Healing Our Land, Inc. and The Massachusetts Black Legislative Caucus Convene 'Prevention Is Power' Community Forum on the Impact of HIV/AIDS on Communities of Color in Massachusetts 2Health News:Google, Yahoo 'Personal Trainers' Strengthen Digital Delts, Partner With Saatchi & Saatchi Healthcare Communications Group Teams in Tech Circuit Training 2Health News:Google, Yahoo 'Personal Trainers' Strengthen Digital Delts, Partner With Saatchi & Saatchi Healthcare Communications Group Teams in Tech Circuit Training 3Health News:Coalition to Protect Senior Care: Bush Budget Plan Dangerous to Seniors' Front Line Care Needs 2Health News:Coalition to Protect Senior Care: Bush Budget Plan Dangerous to Seniors' Front Line Care Needs 3Health News:Low-Carb Diets Better Than Low-Fat Diets at Preventing Diabetes 2Health News:Low-Carb Diets Better Than Low-Fat Diets at Preventing Diabetes 3
A steerable diagnostic catheter with optimal maneuverability...
... Biosense Webster is the source for a ... diagnostic catheters for left-sided mapping - all ... you've come to expect from the leader ... coronary sinus diagnostic catheters are specifically designed ...
Xtrem Dynamic is a line of steerable diagnosis catheters with micro handle. These catheters have been designed to provide pacing and recording during invasive electrophysiology procedures....
... Biosense Webster is the source for a ... diagnostic catheters for left-sided mapping - all ... you've come to expect from the leader ... coronary sinus diagnostic catheters are specifically designed ...
Medicine Products: